Zoetis Inc. (ZTS)
Animal health medicines, research counted. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 12, 2026. Ranked 81 of the 95 Healthcare companies read so far, by the share within reach now.
Within reach now
19%
End of 2028
43%
Employees, annual report
14,500
Leading staffing pattern
Pharmaceutical and Medicine Manufacturing
Share of the working time within reach, long-run pace, four times in five
- Now19%
- End of 202735%
- End of 202843%
- End of 203047%
What changes for its people by the end of 2028, by its industries' figures
- Stays with people 54%
- Becomes checking a model's work 38%
- Handed over with lighter checks 4%
The filing states 14,500 employees, 6,800 in the U.S., with 3,900 in sales and 1,700 in R&D, making animal health medicines, vaccines and diagnostics.
The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.
What follows from the reading
Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 35% at the end of 2027, 43% at the end of 2028, 47% at the end of 2030. By the patterns, the work is about 47% desk work, 14% people work and 39% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 54% of the working time stays with people (conversation, in-person and hands-on work), 38% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.
Headcount
14,500 employees as of December 31, 2025 (stated). Approximately 6,800 of 14,500 employees in the U.S. (47%) and 7,700 in other jurisdictions, stated.
The filing: “As of December 31, 2025, we had approximately 14,500 employees worldwide, which included approximately 6,800 employees in the U.S. and approximately 7,700 in other jurisdictions.”
The workforce as industry patterns
| Pattern | Share | Reason, from the filing |
|---|---|---|
| Pharmaceutical and Medicine Manufacturing | 88% | The animal health medicines, vaccines and diagnostics the company makes and sells, with its sales organization of approximately 3,900 (a) and its manufacturing and administrative staff by description (c), are pharmaceutical and medicine manufacturing, as the other pharmaceutical readings are. |
| Scientific Research and Development Services | 12% | The filing counts approximately 1,700 employees in its global R&D operations (a), read apart at scientific research and development as Regeneron's counted research organization was. |
What the filing says about the workforce: 6,800 in the U.S. and 7,700 elsewhere; about 3,900 in the sales organization and 1,700 in R&D; some employees in unions, works councils or collective bargaining in particular jurisdictions, a small number in the U.S.; voluntary attrition 7% in 2025; engagement 87%.
Companies read with the same leading pattern
Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.
- Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
- Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
- Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
- Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
- AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
- Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
- Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
- Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028
What the filing says about AI
30 sentences in the filing name AI. Thirty sentences: the company added AI dermatology, fecal, urine sediment and mass detection to its Vetscan Imagyst diagnostic platform and launched an AI-powered hematology analyzer, and names AI in its risk factors.
- “In 2023, the company enhanced its Vetscan Imagyst ® platform by adding artificial intelligence (AI) dermatology and AI fecal for equine, which uses a combination of image recognition technology, algorithms and cloud-based AI to deliver rapid testing results to veterinary clinics.”
- “In 2024, the company added AI urine sediment analysis to the Vetscan Imagyst platform and launched Vetscan OptiCell TM a cartridge-based, AI powered hematology analyzer that provides advanced Complete Blood Count (CBC) analysis.”
- “In 2025, the company added AI Masses, which detects potentially neoplastic cells, to the Vetscan Imagyst platform.”
- “Risk Factors--Risks related to legal matters and regulation--Our operations and reputation may be impacted if we do not comply with complex and continually evolving laws and regulations regarding data privacy, processing, and security and the use of AI. 11 | Table of Contents We are also subject to an increasingly complex and growing number of laws, regulations, and directive governing cybersec...”
- “Our business involves using AI to provide faster, more accurate in-clinic diagnostic results and improve research efficiency and accelerated animal health drug discovery.”
Its annual reports, year by year
Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector
- Fiscal 20212median 0
- Fiscal 20222median 0
- Fiscal 20233median 1
- Fiscal 20243median 4
- Fiscal 202530median 10
Headcount by filing year
As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.
| Period | Employees | Filed | Filing |
|---|---|---|---|
| 2025-12-31 | 14,500 | 2026-02-12 | 10-K |
| 2024-12-31 | 13,800 | 2025-02-13 | 10-K |
| 2023-12-31 | 14,100 | 2024-02-13 | 10-K |
| 2022-12-31 | 13,800 | 2023-02-14 | 10-K |
| 2021-12-31 | 12,100 | 2022-02-15 | 10-K |
| 2020-12-31 | 11,300 | 2021-02-16 | 10-K |
| 2019-12-31 | 10,600 | 2020-02-13 | 10-K |
| 2018-12-31 | 10,000 | 2019-02-14 | 10-K |
| 2017-12-31 | 9,200 | 2018-02-15 | 10-K |
| 2016-12-31 | 9,000 | 2017-02-16 | 10-K |
| 2015-12-31 | 9,000 | 2016-02-24 | 10-K |
| 2014-12-31 | 1,100 | 2015-02-27 | 10-K |
| 2013-12-31 | 1,100 | 2014-03-26 | 10-K |
| 2012-12-31 | 1,000 | 2013-03-28 | 10-K |
Limits of this reading
- The R&D count (1,700) is read apart; the sales organization (3,900) stays inside the pharmaceutical pattern as a counted part of it.
- The data service's segment table mislabels the species and was not used.
Source: the company's annual report on EDGAR, accession 0001555280-26-000011, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.
The report on Zoetis Inc., $29
This page as a document to keep, with what it does not show: the share within reach at every date on three paces and two reliabilities, a typical workforce of this shape at the stated headcount role by role and task by task (the industries' staffing, never the company's roster), where to start, what changes for the people and what they would learn, every sentence in the filing that names AI, the headcount by year, the companies read with the same leading pattern, the method and a citation line. To print or save as a PDF, open again in your browser for a year.
See the report, $29See the sample first: Walmart's report is free
Questions about this company
- How much of Zoetis Inc.'s working time is within reach of AI?
- An estimated 19% now and 43% by the end of 2028, on METR's long-run pace at four in five, from the workforce Zoetis Inc.'s own annual report describes and BLS staffing patterns for its industries, never from a roster. It is an estimate with a stated method. It is not a forecast of jobs lost or of savings, and it says nothing about what the company will do.
- How many people does Zoetis Inc. employ?
- 14,500 as of December 31, 2025, as its annual report for the period ending December 31, 2025 states. About 47% in the U.S.
- What kinds of work make up Zoetis Inc.'s workforce?
- Read from its annual report as a blend of 2 industry staffing patterns, the largest Pharmaceutical and Medicine Manufacturing; by those patterns the work is about 47% desk work, 14% people work and 39% body work. Each share has a one-sentence reason on this page that can be checked against the filing.
- What does Zoetis Inc.'s annual report say about AI?
- 30 sentences in the filing name AI. Its annual reports for fiscal 2021 to 2025 name it in 2, 2, 3, 3 and 30 sentences, year by year. They are counted and quoted on this page, never judged: a count says how much a filing talks about AI, not what the company does with it.
- How is this estimated?
- Claude Fable 5.1 read the annual report under the Index's written rubric (version 1) on October 19, 2026: the stated headcount, the share in the U.S. when stated, and the workforce as a blend of industry staffing patterns. The estimates are the site's industry estimates weighted by those shares, from O*NET tasks with estimated lengths and METR's measurements of how long a task AI models can finish. A company can write to info@stratussc.com to have its reading checked against its filing.
Embed these figures on your site
A small card with the share of working time within reach now and at the end of 2027, 2028 and 2030, the date and a link back. Free under CC BY 4.0; the card carries the credit.